|
Age (> 60 years vs. ≤ 60 years)
|
1.88 (0.57–6.19)
|
0.298
| | | | |
|
Sex (men vs. women)
|
0.62 (0.21–1.85)
|
0.389
| | | | |
|
Site of tumor (gastric vs. non-gastric)
|
1.19 (0.40–3.57)
|
0.752
| | | | |
|
Size (> 5 cm vs. ≤ 5 cm)
|
3.83 (1.05–13.98)
|
0.042*
| | | | |
|
Mitotic count per HPFs (> 5 vs. ≤ 5)
|
4.27 (1.31–13.89)
|
0.016*
| | | | |
|
Resection (R1 vs. R0)
|
2.48 (0.32–19.45)
|
0.389
| | | | |
|
Modified NIH consensus criteria (high-risk group vs. the other risk groups)
|
4.67 (1.28–16.98)
|
0.019*
|
0.34 (0.05–2.26)
|
0.261
|
0.33 (0.048–2.24)
|
0.255
|
|
Adjuvant imatinib treatment (yes vs. no)
|
4.89 (1.62–14.77)
|
0.005*
|
1.28 (0.34–4.77)
|
0.715
|
1.39 (0.36–5.35)
|
0.632
|
|
SUVmax (≥ 7.04 vs. < 7.04)
|
13.46 (2.98–60.75)
|
0.001*
|
4.44 (0.79–25.00)
|
0.091
|
3.43 (0.53–22.17)
|
0.196
|
|
MTV (≥ 54.76 cm3 vs. < 54.76 cm3)
|
19.79 (4.37–89.67)
|
< 0.001*
|
17.69 (2.03–154.17)
|
0.009*
| | |
|
TLG (≥ 228.79 g vs. < 228.79 g)
|
22.24 (4.91–100.77)
|
< 0.001*
| | |
20.48 (2.19–191.16)
|
0.008*
|
